B70

(I) antigen is prepd. by reaction of 1 of the peptides (as hapten) and carrier in the presence of hapten-carrier binding agent. Carriers may be natural and synthetic proteins, e.g. animal serum albumin (human serum albumin, bovine serum albumin), animal serum globulin, animal thyroglobulin, animal hemoglobulin, lysine-glutamic acid copolymer, polylysine, polyglutamic acid, etc.. Binding agents are, e.g. aliphatic dialdehydes (glyoxal, malondialdehyde), dimaleimides (N,N'-o-phenylene-dimaleimide), maleimide-carboxyl -N-hydroxysuccinimide-esters, carbodiimides, etc..

```
? S PN=JP 61073665
      S8         1  PN=JP 61073665
? T 8/3,AB/1
```

8/3,AB/1

DIALOG(R)File 351:Derwent WPI

004632176
WPI Acc No: 1986-135519/*198621*
XRAM Acc No: C86-058161
XRPX Acc No: N86-100158

Protecting wounds by artificial membrane - by applying soln. contg. anionic polymer and calcium salt soln. contg. cationic polymer to wound

Patent Assignee: KUMABE K (KUMA-I)
Number of Countries: 001 Number of Patents: 001
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
JP 61073665	A	19860415	JP 84195767	A	19840920	198621	B

Priority Applications (No Type Date): JP 84195767 A 19840920
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
JP 61073665	A		4		

Abstract (Basic): JP 61073665 A

First soln. is prepd. by heating and sterilising at least one anionic macromilecular material aq. soln.. The second soln. is prepd. by adding a calcium salt aq. soln. to at least one cationic macromolecular material aq. solution and by heating and sterilising the calcium salt aw. soln-contg. cationic macromolecular material aq. soln.. The first soln. and the second soln. are applied to a wound and the surrounding area to form a membrane.

The first soln. is a 0.1-10.0% anionic macromolecular aq. soln.. The second soln. is a soln. prepd. to pH 5 by adding a 5-10.0 % Ca salt aq.soln. to a 0.1-5.0 % cationic macromolecular aq. soln. The anionic macromolecular material i sthat selected from xanthan gum, alginic acid, and galacturonic acid. The cationic macromolecular material is that selected from chitosan, polylysine and copolymer of dihydroxyethylaminopropyl and glutamic acid. The first soln. and the second soln. are sprayed at the wound and the surrounding area.

USE/ADVANTAGE - The membrane developed has good adhesion to a skin, resulting in protecting the wound and eliminating the need for applying a gauze to the wound.

```
? S PN=JP 63253028
      S9         1  PN=JP 63253028
? T 9/3,AB/1

 9/3,AB/1
DIALOG(R)File 351:Derwent WPI
(c) 2003  Thomson Derwent. All rts. reserv.

007707565
WPI Acc No: 1988-341497/*198848*
XRAM Acc No: C88-150996
  Biocompatibility promoters - comprises cpd. obtd. by reaction of prod. of
  protein toxin from enterotoxin, abrin, ricin or viscotoxin and amino-gp.
  modifying agent
Patent Assignee: KAO CORP (KAOS  )
Number of Countries: 001  Number of Patents: 001
Patent Family:
Patent No      Kind   Date     Applicat No    Kind   Date      Week
JP 63253028     A   19881020  JP 8786632      A   19870408  198848  B

Priority Applications (No Type Date): JP 8786632 A 19870408
Patent Details:
Patent No  Kind Lan Pg   Main IPC    Filing Notes
JP 63253028   A      7

Abstract (Basic): JP 63253028 A
        Promotors contain as active component a cpd. obtd. with a reaction
    of (a) 1 mol of protein toxin selected from cholera enterotoxin, abrin,
    ricin or viscotoxin and (b) 1-10 mol of amino radical chemically
    modifying agent.
         Pref. abrin is obtd. from seed of Abrus precatorium L. Viscotoxin
    is obtd. from the plant (Viscum albam L). The chemically modifying
    agent is polyethyleneoxide, 3,5-bis(o-methoxy polyethyleneglycol)
    triazine; a copolymer of lysine and polyaspartic acid, polyalanine,
    polylysine or glutamic acid; 3,5-bis(pullulan) triazine, dextran;
    propionic acid, capronic acid, caproic acid, lauric acid, etc.
         USE/ADVANTAGE - Promoters are useful for immuno rejection reaction
    inhibitors.
? S PN=FR 2092875
     S10         1  PN=FR 2092875
? T 10/3,AB/1

 10/3,AB/1
DIALOG(R)File 351:Derwent WPI
(c) 2003  Thomson Derwent. All rts. reserv.

000866188
WPI Acc No: 1972-26165T/*197217*
  Interferon stimulants - dialkylaminoalkyl dextran-nucleic acid comple
Patent Assignee: MAES RFE (MAE -I)
Number of Countries: 002  Number of Patents: 002
Patent Family:
Patent No      Kind   Date     Applicat No    Kind   Date      Week
FR 2092875      A                                             197217  B
US 3679654      A                                             197232

Priority Applications (No Type Date): FR 7023769 A 19700626
```


[redacted]